Journal of Translational Medicine,
Год журнала:
2025,
Номер
23(1)
Опубликована: Апрель 15, 2025
Cancer
immunotherapy
aims
to
harness
the
body's
own
immune
system
for
effective
and
long-lasting
elimination
of
malignant
neoplastic
tissues.
Owing
advance
in
understanding
cancer
pathology
immunology,
many
novel
strategies
enhancing
immunological
responses
against
various
cancers
have
been
successfully
developed,
some
translated
into
excellent
clinical
outcomes.
As
one
promising
strategy
next
generation
immunotherapies,
activating
multi-cellular
network
(MCN)
within
tumor
microenvironment
(TME)
deploy
multiple
mechanisms
action
(MOAs)
has
attracted
significant
attention.
To
achieve
this
effectively
safely,
delivering
or
pleiotropic
therapeutic
cargoes
targeted
sites
cancerous
tissues,
cells,
intracellular
organelles
is
critical,
which
numerous
nanocarriers
developed
leveraged.
In
review,
we
first
introduce
payloads
categorized
according
their
predicted
functions
physicochemical
structures
forms.
Then,
nanocarriers,
along
with
unique
characteristics,
properties,
advantages,
limitations,
are
introduced
notable
recent
applications
immunotherapy.
Following
discussions
on
targeting
strategies,
a
summary
each
nanocarrier
matching
suitable
provided
comprehensive
background
information
designing
regimens.
Nano-Micro Letters,
Год журнала:
2025,
Номер
17(1)
Опубликована: Фев. 21, 2025
The
emerging
messenger
RNA
(mRNA)
nanomedicines
have
sprung
up
for
disease
treatment.
Developing
targeted
mRNA
has
become
a
thrilling
research
hotspot
in
recent
years,
as
they
can
be
precisely
delivered
to
specific
organs
or
tissues
enhance
efficiency
and
avoid
side
effects.
Herein,
we
give
comprehensive
review
on
the
latest
progress
of
with
targeting
functions.
its
carriers
are
first
described
detail.
Then,
mechanisms
passive
targeting,
endogenous
active
outlined,
focus
various
biological
barriers
that
may
encounter
during
vivo
delivery.
Next,
emphasis
is
placed
summarizing
mRNA-based
organ-targeting
strategies.
Lastly,
advantages
challenges
clinical
translation
mentioned.
This
expected
inspire
researchers
this
field
drive
further
development
technology.
Applied Biosciences,
Год журнала:
2025,
Номер
4(1), С. 16 - 16
Опубликована: Март 5, 2025
Hematologic
malignancies,
including
leukemia,
lymphoma,
and
multiple
myeloma,
pose
significant
therapeutic
challenges
due
to
their
heterogeneity
high
relapse
rates.
Nanotechnology
has
emerged
as
a
promising
avenue
for
precision
drug
delivery
in
these
allowing
enhanced
concentration
at
tumor
sites
reducing
systemic
toxicity.
Recent
developments
nanocarriers—such
liposomes,
polymeric
nanoparticles,
inorganic
nanoparticles—have
enabled
targeted
approaches,
utilizing
molecular
markers
specific
malignant
cells
increase
efficacy
while
minimizing
adverse
effects.
Evidence
from
preclinical
clinical
studies
underscores
the
potential
of
nanotechnology
improve
patient
outcomes
by
facilitating
controlled
release,
improved
bioavailability,
reduced
However,
translating
advancements
into
practice
requires
further
research
validate
safety
efficacy.
This
review
provides
comprehensive
analysis
latest
innovations
hematologic
addressing
current
achievements
future
directions
integrating
approaches
Clinical
Hemato-Oncology.
Molecular Therapy — Nucleic Acids,
Год журнала:
2025,
Номер
36(2), С. 102520 - 102520
Опубликована: Март 20, 2025
Efficient
delivery
of
mRNA-lipid
nanoparticles
(LNPs)
to
specific
cell
types
remains
a
major
challenge
for
mRNA
therapeutics.
Conventional
targeting
approaches
involve
modifying
the
lipid
composition
or
functionalizing
surface
LNPs,
which
complicates
manufacturing
and
alters
nanoparticle
size,
charge,
stealth,
impacting
their
immunogenicity.
Here,
we
present
generalizable
method
targeted
mRNA-LNP
that
uses
bispecific
antibodies
(BsAbs)
form
bridge
between
LNPs
markers.
BsAbs
can
be
combined
with
administered
first,
binding
proteins
on
target
cells
later
retaining
unmodified
in
affected
tissues.
We
demonstrate
efficient
cell-type-specific
mRNA-LNPs
beyond
liver,
epidermal
growth
factor
receptor
(EGFR)-
folate
hydrolase
1
(PSMA)-positive
vitro
vivo.
The
flexibility
this
technology,
achieved
by
substituting
cell-targeting
region
BsAbs,
enables
rapid
development
next-generation
drugs.
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 25, 2025
Ribonucleic
acid
(RNA)-based
therapies
represent
a
promising
class
of
drugs
for
the
treatment
non-small
cell
lung
cancer
(NSCLC)
due
to
their
ability
modulate
gene
expression.
Therapies
leveraging
small
interfering
RNA
(siRNA),
messenger
(mRNA),
microRNA
(miRNA),
and
antisense
oligonucleotides
(ASOs)
offer
various
advantages
over
conventional
treatments,
including
target
specific
genetic
mutations
potential
personalized
medicine
approaches.
However,
clinical
translation
these
therapeutics
NSCLC
faces
challenges
in
delivery
immunogenicity,
negative
charge,
large
size,
which
can
be
mitigated
with
platforms.
In
this
review,
we
provide
description
pathophysiology
an
overview
RNA-based
therapeutics,
specifically
highlighting
application
NSCLC.
We
discuss
relevant
classes
therapeutic
then
non-viral
strategies
such
as
lipid-
polymer-based
nanoparticles
that
have
been
developed
address
issues
preclinical
models.
Furthermore,
summary
table
trials
leverage
[which
includes
National
Clinical
Trial
(NCT)
numbers]
highlight
current
progress
also
how
integrated
existing
modalities
enhance
efficacy
improve
patient
outcomes.
Overall,
aim
tackle
while
showcasing
RNA's
next-generation
therapy
treatment.
Biomacromolecules,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 31, 2025
Combining
an
amphiphilic
block
copolymer
polybutadiene-b-poly(ethylene
glycol)
(PBD-b-PEO),
ionizable
lipid,
a
helper
and
cholesterol
produces
thermostable
BNPs.
Luciferase
mRNA-BNPs
can
be
stored
for
over
1
year
at
4
°C
with
no
evidence
of
degradation
to
the
mRNA
or
nanocarrier.
In
vivo,
exhibit
greater
affinity
secondary
lymphoid
organs
than
mRNA-lipid
nanoparticles
(LNPs)
are
efficiently
taken
up
by
macrophages
dendritic
cells.
Freshly
fabricated
ovalbumin
(OVA)
elicit
robust
OVA-specific
IgG
functional
memory
CD8+
T
cells
that
persist
least
5
months.
Immunogenicity
remains
intact
after
24
weeks
storage
°C.
Anti-PEG
antibodies
not
boosted
repeated
administration
mRNA-BNPs,
unlike
mRNA-LNPs.
Syrian
hamsters
vaccinated
SARS-CoV-2
spike
protected
against
weight
loss
associated
infection
potently
suppress
pulmonary
viral
loads.
Protective
efficacy
is
comparable
conferred
Comirnaty
biosimilar.
Cumulatively,
thermostable,
immunogenic
possess
potential
clinical
application.
Advanced Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
mRNA
therapeutics
hold
tremendous
promise
for
disease
prevention
and
treatment.
Development
of
high-performance
delivery
systems
with
enhanced
transfection
efficiency
a
safety
profile
will
further
fulfill
their
therapeutic
potential
expedite
translation.
The
synthesis
"four-in-one"
highly
branched
poly(β-amino
ester)s
(O-LhPAEs)
is
reported
by
integrating
the
essential
components
lipid
nanoparticles
(LNPs)
spleen-selective
enrichment
nebulization
treatment
silicosis.
60
O-LhPAEs
distinct
structure
chemical
composition,
including
tertiary/quaternary
amines,
cholesterol
moieties,
zwitterionic
species,
hydrophobic
alkyl
tails,
are
synthesized
using
sequential
Michael
addition,
ring-opening,
nucleophilic
substitution
reactions.
unique
topological
composition
collectively
O-LhPAEs/mRNA
polyplex
serum
resistance,
cellular
uptake,
endosomal
escape.
optimal
O-LhPAE,
20%b-3C-2P12,
exhibits
up
to
93.1%
across
11
different
cell
types,
epithelial
cells,
fibroblasts,
cancer
stem
neurological
astrocytes.
Biodistribution
study
reveals
that
20%b-3C-2P12/mRNA
polyplexes
mainly
enriched
in
spleen
following
systemic
administration.
Through
nebulization,
20%b-3C-2P12
mediated
high
Tbx2
expression
lungs
silicosis
mice,
effectively
restoring
lung
functions.
This
not
only
establishes
strategy
development
LNP-like
but
also
provides
promising
candidates
safe,
efficient,
